J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Adverse Event Rates

Johnson & Johnson (JNJ) has reported that its subcutaneous formulation of RYBREVANT FASPRO in combination with LAZCLUZE demonstrates lower rates of certain adverse events compared to the standard intravenous regimen.

The company disclosed that the subcutaneous administration of RYBREVANT FASPRO, when combined with LAZCLUZE, resulted in lower incidence rates of rash and administration-related reactions. Additionally, the data indicated a reduction in venous thromboembolism (VTE) rates associated with this delivery method.

The comparison was made against the intravenous MARIPOSA regimen, which is the current standard treatment protocol.